Evidence map›Paper›PMID 34414384›Full record

ArticleMed (New York, N.Y.)2021

Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases.

Claire T Deakin, Georgina H Cornish, Kevin W Ng, Nikhil Faulkner, William Bolland, Joshua Hope, Annachiara Rosa, Ruth Harvey, Saira Hussain, Christopher Earl and 21 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Med (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Human Endogenous Retroviruses Expression in Autoimmunity.The Yale journal of biology and medicine · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 4 institutions in 1 country.

Claire T DeakinCentre for Adolescent Rheumatology Versus Arthritis at University College London (UCL), University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), London, UK.
Georgina H CornishRetroviral Immunology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Kevin W NgRetroviral Immunology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Nikhil FaulknerRetroviral Immunology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
William BollandRetroviral Immunology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Joshua HopeChromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Annachiara RosaChromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Ruth HarveyWorldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Saira HussainWorldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Christopher EarlSignalling and Structural Biology Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Bethany R JebsonCentre for Adolescent Rheumatology Versus Arthritis at University College London (UCL), University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), London, UK.
Meredyth G L L WilkinsonCentre for Adolescent Rheumatology Versus Arthritis at University College London (UCL), University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), London, UK.
Lucy R MarshallCentre for Adolescent Rheumatology Versus Arthritis at University College London (UCL), University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), London, UK.
Kathryn O'BrienCentre for Adolescent Rheumatology Versus Arthritis at University College London (UCL), University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), London, UK.
Elizabeth C RosserCentre for Adolescent Rheumatology Versus Arthritis at University College London (UCL), University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), London, UK.
Anna RadziszewskaCentre for Adolescent Rheumatology Versus Arthritis at University College London (UCL), University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), London, UK.
Hannah PeckhamCentre for Adolescent Rheumatology Versus Arthritis at University College London (UCL), University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), London, UK.
Harsita PatelSection of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, London, UK.
Judith HeaneyUCLH NHS Trust, London NW1 2BU, UK.
Hannah RickmanUCLH NHS Trust, London NW1 2BU, UK.
Stavroula ParaskevopoulouUCLH NHS Trust, London NW1 2BU, UK.
Catherine F HoulihanUCLH NHS Trust, London NW1 2BU, UK.
Moira J SpyerUCLH NHS Trust, London NW1 2BU, UK.
Steve J GamblinStructural Biology of Disease Processes Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
John McCauleyWorldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Eleni NastouliUCLH NHS Trust, London NW1 2BU, UK.
Michael LevinSection of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, London, UK.
Peter CherepanovChromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Coziana CiurtinCentre for Adolescent Rheumatology Versus Arthritis at University College London (UCL), University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), London, UK.
Lucy R WedderburnCentre for Adolescent Rheumatology Versus Arthritis at University College London (UCL), University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), London, UK.
George KassiotisRetroviral Immunology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
The Francis Crick Institute · GBGreat Ormond Street Hospital · GBImperial College London · GBUniversity College London · GB

Funding

Cancer Research UKMedical Research Council MR/M004600/1Medical Research Council MR/R013926/1Versus Arthritis 21552Versus Arthritis 22203
6 · The paper itself

Abstract

backgroundDifferences in humoral immunity to coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), between children and adults remain unexplained, and the effect of underlying immune dysfunction or suppression is unknown. Here, we sought to examine the antibody immune competence of children and adolescents with prevalent inflammatory rheumatic diseases, juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), and juvenile systemic lupus erythematosus (JSLE) against the seasonal human coronavirus (HCoV)-OC43 that frequently infects this age group.

methodsSera were collected from JIA (n = 118), JDM (n = 49), and JSLE (n = 30) patients and from healthy control (n = 54) children and adolescents prior to the coronavirus disease 19 (COVID-19) pandemic. We used sensitive flow-cytometry-based assays to determine titers of antibodies that reacted with the spike and nucleoprotein of HCoV-OC43 and cross-reacted with the spike and nucleoprotein of SARS-CoV-2, and we compared them with respective titers in sera from patients with multisystem inflammatory syndrome in children and adolescents (MIS-C).

findingsDespite immune dysfunction and immunosuppressive treatment, JIA, JDM, and JSLE patients maintained comparable or stronger humoral responses than healthier peers, which was dominated by immunoglobulin G (IgG) antibodies to HCoV-OC43 spike, and harbored IgG antibodies that cross-reacted with SARS-CoV-2 spike. In contrast, responses to HCoV-OC43 and SARS-CoV-2 nucleoproteins exhibited delayed age-dependent class-switching and were not elevated in JIA, JDM, and JSLE patients, which argues against increased exposure.

conclusionsConsequently, autoimmune rheumatic diseases and their treatment were associated with a favorable ratio of spike to nucleoprotein antibodies.

fundingThis work was supported by a Centre of Excellence Centre for Adolescent Rheumatology Versus Arthritis grant, 21593, UKRI funding reference MR/R013926/1, the Great Ormond Street Children's Charity, Cure JM Foundation, Myositis UK, Lupus UK, and the NIHR Biomedical Research Centres at GOSH and UCLH. This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust

Indexed as

Autoimmune DiseasesCoronavirus OC43, HumanCOVID-19Rheumatic DiseasesAdolescentAdultAntibodies, ViralAntibody FormationChildHumansImmunoglobulin GNucleoproteinsSARS-CoV-2Spike Glycoprotein, CoronavirusSystemic Inflammatory Response SyndromeAntibodies, ViralImmunoglobulin GNucleoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibody responseimmunosuppressionnucleoproteinrheumatic diseasesSARS-CoV-2seasonal coronavirusspike protein

Identifiers

PMID34414384
PMCPMC8363467
OpenAlexW3196053940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.